George W. Sledge Jr., M.D.

Medical oncologist, Breast specialist

Professor of Medicine (Oncology) at the Stanford University Medical Center

Breast Cancer Program

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Women's Cancer Center

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Board Certification: Medical Oncology, American Board of Internal Medicine (1983)

Fellowship: The University of Texas at San Antonio (1983) TX

Board Certification: Internal Medicine, American Board of Internal Medicine (1980)

Residency: St Louis University Hospital (1980) MO

Medical Education: Tulane University School of Medicine (1977) LA

Honors & Awards

HOPE Funds for Cancer Research 2013 Award of Excellence for Medicine, HOPE Funds, Cancer Research (April 28, 2013)

President, American Society of Clinical Oncology, American Society of Clinical Oncology (ASCO) (2010-2011)

Editor-In-Chief, Clinical Breast Cancer (1999-present)

Chair, Breast Committee, Eastern Cooperative Oncology Group (ECOG) (2002-2010)

APEX Award for Publication Excellence in the category of "Regular Departments & Columns", Oncology Times (2012)

Health Care Hero award, Indianapolis Business Journal (2011)

William L. McGuire Award, San Antonio Breast Cancer Symposium (2010)

Jill Rose Award, Breast Cancer Foundation (2007)

Komen Brinker Award for Scientific Distinction, Susan G. Komen Breast Cancer Foundation (2006)

Listed in "America's Top Doctors", Castle Connolly (2001-2012)

Ballve-Lantero Chair (Endowed Chair), Ballve-Lantero (1996)

Administrative Appointments

Professor, and Chief, Division of Oncology, Stanford University Medical Center (2013 - Present)

ASCO's approach to a learning health care system in oncology.
Sledge, G. W., Hudis, C. A., Swain, S. M., Yu, P. M., Mann, J. T., & Lichter, A. S. (2013). ASCO's approach to a learning health care system in oncology. Journal of oncology practice / American Society of Clinical Oncology, 9(3), 145-148.

CancerLinQ and the Future of Cancer Care.
Sledge, G. W., Miller, R. S., & Hauser, R. (2013). CancerLinQ and the Future of Cancer Care. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, 2013, 430-434.

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
Carlson, R. W., O'Neill, A., Vidaurre, T., Gomez, H. L., Badve, S. S., & Sledge, G. W. (2012). A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 133(3), 1049-1056.

Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R., Silver, D. P., & Carey, L. A. (2010). Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH, 16(19), 4702-4710.